HealthQuill Cancer
Gilead Sciences and Kymera Therapeutics have signed a $750 million license agreement to develop a new cancer medicine to treat breast cancer and other solid tumours.Ā 
Drugs Health Pharma

Gilead, Kymera Therapeutics in $750m pact to make new cancer drug

HQ Team June 25, 2025: Gilead Sciences Inc. and Kymera Therapeutics have signed a $750 million license agreement to develop a new cancer.

Read More
Madrigal Pharmaceuticals EU Limited's therapy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) got a conditional marketing authorisation in the European Union.Ā 
Drugs Health Medical

Madrigalā€™s therapy to treat MASH in adults gets EU’s initial nod

HQ Team June 22, 2025: Madrigal Pharmaceuticals EU Limited’s therapy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) got a conditional marketing.

Read More
The US drug regulator has put on hold two trials of Gilead Sciences Inc., testing a combination of two of its investigational HIV treatments, after some patients developed lower immune cell counts.
Drugs Health Pharma

Gilead Sciencesā€™ HIV experimental trials put on hold by US drug regulator

HQ Team June 11, 2025: The US drug regulator has put on hold two trials of Gilead Sciences Inc., testing a combination of.

Read More
Lupin Pharma
Drugs Health Research

Role of vitamins and diets in cancer prevention, treatment

HQ Team May 15, 2025: A recent meta research by DrĀ Salvatore CortellinoĀ and ProfessorĀ Antonio Giordano, President of theĀ Sbarro Health Research OrganizationĀ (SHRO) and molecular oncologist.

Read More
FDA has granted full approval for Janssen Biotechā€™s Balversa drug to treat metastatic bladder cancer after clinical trials showed ā€œsignificantā€ improvement in overall survival rates.
Uncategorized

Study sees rising cancer cases in young adults; death rates remain stable

HQ Team May 8, 2025: In a surprising and concerning trend, new research from theĀ National Institutes of Health (NIH)Ā reveals thatĀ 14 types of cancerĀ are.

Read More
Britainā€™s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer therapy, nivolumab (Opdivo), offering a quicker administration option for eligible patients than the currently available drip treatment.Ā 
Drugs Medical Pharma

UK regulator clears subcutaneous injection of Bristol Myers for cancers

HQ Team May 1, 2025: Britainā€™s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer.

Read More
IntraBio Inc, a biotechnology company focused on rare and neurodegenerative diseases, got the US regulatorā€™s nod for a drug to treat a certain type of Niemann-Pick disease in adults and pediatric patients weighing about 15 kilograms.
Health

Primary care clinics can help detect 10% of cancers caused by genes

HQ Team March 10, 2025: Patient screening in primary care settings can detect up to 10% of cancers caused by genes. Easily available.

Read More
US scientists have blocked a protein that kills a variety of cancer cells in an experiment on mice, pointing to a new potential target for cancer treatment, according to the National Institutes of Health.
Drugs Health Research

US scientists block proteins that aid cancer cells’ group strategy to survive

HQ Team March 5, 2025: US scientists have blocked a protein that kills a variety of cancer cells in an experiment on mice,.

Read More
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the worldā€™s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
HyundaiĀ ADM Bio, a subsidiary of South Koreaā€™s Hyundai Bioscience, unveiled an oral cancer drug that allows patients to make a shift from intravenous chemotherapy.
Health Medical Pharma

South Koreaā€™s Hyundai ADM unveils oral chemotherapy drug

HyundaiĀ ADM Bio, a subsidiary of South Koreaā€™s Hyundai Bioscience, unveiled an oral cancer drug that allows patients to make a shift from intravenous.

Read More